If you have tried two or three antidepressants that either did nothing or caused side effects you could not tolerate, you may have heard about the GeneSight test. It is a cheek-swab genetic test that sorts psychiatric medications by how your genes may affect the way your body handles them. The marketing suggests a shortcut to the right prescription. The research on GeneSight testing tells a more modest story.
Pharmacogenomic Testing Looks at How Your Genes Process Medication
Pharmacogenomic (PGx) testing looks for inherited gene differences that affect how drugs are broken down and how they act in the body. The most useful information comes from liver enzymes in the cytochrome P450 (CYP) family, especially CYP2D6 and CYP2C19, which process many antidepressants and antipsychotics.
Based on your variants, you may be classified as a poor, intermediate, normal, or ultrarapid metabolizer. Poor metabolizers clear certain drugs slowly, so levels can build up and cause side effects at standard doses. Ultrarapid metabolizers clear them quickly, so a standard dose may not reach an effective level.
The FDA's Table of Pharmacogenetic Associations includes several psychiatric drugs. For example, it lists a 20 mg maximum citalopram dose for CYP2C19 poor metabolizers and recommends dose adjustments for aripiprazole and atomoxetine in CYP2D6 poor metabolizers.
How the GeneSight Test Works
GeneSight Psychotropic is made by Myriad Genetics. Here is the process:
- A registered prescriber, such as a psychiatrist, primary care physician, or nurse practitioner, orders the test.
- You provide a cheek swab in the office or with a mailed home kit.
- Results usually reach your prescriber about three days after the lab receives the sample, and your prescriber reviews them with you.
14 Genes Used for Medication Categories, Plus One Informational Gene
The GeneSight product page lists 15 genes in total. Fourteen of them, in two groups, are used to place medications into categories:
- Nine metabolism (pharmacokinetic) genes: CYP2D6, CYP2C19, CYP2C9, CYP1A2, CYP2B6, CYP3A4, CES1, UGT1A4, and UGT2B15
- Five drug response (pharmacodynamic) genes: SLC6A4 (the serotonin transporter), HTR2A (a serotonin receptor), ADRA2A, and two immune system markers (HLA-A and HLA-B variants) linked to serious skin reactions with carbamazepine
The fifteenth gene, COMT, is reported for informational purposes only and does not set any medication's category.
The company says the report covers more than 60 medications used for depression, anxiety, ADHD, and other conditions. It also notes how smoking may change the metabolism of certain medications.
GeneSight Test Results Use Green, Yellow, and Red Categories
The report places each medication into one of three groups:
- Green, "Use as directed": no variations in the tested genes predict an abnormal response.
- Yellow, "Moderate gene-drug interaction": your prescriber may adjust the dose or monitor more closely.
- Red, "Significant gene-drug interaction": your genes suggest a higher chance of side effects, lower effect, or a need for a different dosing approach.
What the Colors Do Not Mean
Green does not mean a medication will work; the company itself states that patients may not respond to green medications. Red does not mean a drug is off-limits, only that your prescriber should weigh the interaction against everything else known about you. The report also does not diagnose any condition, check for drug-drug interactions or allergies, or identify the best medication.
What the Research on the GeneSight Test Shows
Two large randomized trials, both in adults with major depression, carry the most weight.
The GUIDED Trial Missed Its Primary Goal but Showed Secondary Gains
The GUIDED trial, published in 2019, enrolled 1,167 adults with major depression who had not responded well to at least one antidepressant. Clinicians in one group had GeneSight results; the other group received usual care.
- Primary outcome, not met: average symptom improvement at week 8 was 27.2% with testing vs. 24.4% with usual care, not a statistically significant difference.
- Secondary outcome, response: 26.0% vs. 19.9% at week 8, a significant difference.
- Secondary outcome, remission: 15.3% vs. 10.1% at week 8, also significant.
Secondary results carry less weight when the primary outcome is negative. A review in American Family Physician pointed out that the trial included more poor metabolizers than typical U.S. practice would, which may make the benefit look larger than it would be in everyday care.
The VA PRIME Care Trial Found a Small, Short-Lived Benefit
The PRIME Care trial, published in JAMA in 2022, randomized 1,944 veterans with major depression at 22 VA medical centers. It used the GeneSight panel and had two co-primary outcomes.
- Primary outcome 1, prescribing: clinicians with results were more likely to prescribe an antidepressant with no predicted gene-drug interaction (59.3% vs. 25.7%), a significant difference.
- Primary outcome 2, remission over 24 weeks: modestly higher in the testing group overall (a 2.8 percentage point difference), peaking at week 12 (16.5% vs. 11.2%). By week 24, the difference in remission was no longer significant (17.2% vs. 16.0%).
- Secondary outcomes, response and symptom reduction: both were modestly better in the testing group across the 24 weeks.
The authors called the remission effect small and not persistent, and the trial was not blinded. The trial excluded people with bipolar disorder, psychosis, and active substance use disorder.
Genetic Compatibility Does Not Guarantee a Medication Will Work
In both trials, most people in the testing group still did not reach remission. A medication that fits your genes on paper can still fail, and one flagged for an interaction can still work at an adjusted dose.
Expert Reviews Recommend Selective Use
The American Family Physician review concluded that routine testing is not recommended, and that testing is best reserved for people who have not responded to several medications or had intolerable side effects. As of that review, no peer-reviewed studies had examined GeneSight outcomes in children.
CPIC Guidelines Set the Clinical Standard for Gene-Drug Pairs
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed guidelines on using genetic results in prescribing. Its 2023 antidepressant guideline gives SSRI and SNRI dosing recommendations based on CYP2D6, CYP2C19, and CYP2B6 results.
It also concluded that current evidence on SLC6A4 and HTR2A, both on the GeneSight panel, does not support their use in antidepressant prescribing. The metabolism portion of the report rests on the firmest science.
The GeneSight Test Has Real Limitations
Genes explain only part of how you respond to a medication:
- Diagnosis, dose, time on the medication, and adherence all affect results.
- Other medications, smoking, alcohol, age, and liver function change how fast you clear a drug. Some drugs block the same enzymes, so a normal metabolizer can act like a poor one.
- A red result can steer someone away from a medication that would have helped.
- Waiting for results should not delay treatment you need now.
- The test does not replace a full psychiatric evaluation or clinical judgment.
Lab Quality, FDA Status, and Clinical Usefulness Are Separate Questions
Three kinds of oversight often get blended together in discussions of the GeneSight test, but each answers a different question.
Lab Certification Covers Accuracy
The company states that its laboratory is certified under CLIA (Clinical Laboratory Improvement Amendments) and accredited by CAP (College of American Pathologists). These standards cover lab quality: quality control, staff qualifications, and accurate, reliable genetic results. They say nothing about how useful those results are for choosing a medication.
The Test Has Not Been Through FDA Review
According to the American Family Physician review, GeneSight has not been submitted to the FDA for approval. Tests designed and performed within a single lab, called laboratory-developed tests, have mostly been overseen through CLIA standards rather than FDA review. A 2024 FDA rule would have regulated them as medical devices, but a federal court in Texas vacated it in March 2025. The FDA has also warned that changing a medication based on unreviewed pharmacogenetic claims may lead to incorrect treatment or worsening illness.
Clinical Utility Is Answered by Trials
Clinical utility means that using the results leads to better patient outcomes. Neither lab certification nor FDA status settles that. Randomized trials like GUIDED and PRIME Care test it directly, and they show a modest benefit at best.
Who May Benefit From a GeneSight Test
Testing makes the most sense when standard approaches have not worked, such as when:
- Two or more medication trials have failed at adequate doses and duration
- You had strong side effects at low doses
- You take several medications and interaction risk is a concern
For first-time treatment, most psychiatrists choose a medication from your symptoms and history first. Our guide on what happens when the first prescription does not work covers the usual next steps.
GeneSight Test Cost and Insurance Coverage
What you pay for GeneSight testing depends on your insurance, plan, and eligibility for company programs, and terms can change. The figures below come from the GeneSight cost page at the time of writing. Confirm your own cost with the company before you test.
- Self-pay: the company currently lists a reduced self-pay option of $330 for all patients, which may help if your insurance cost would be higher.
- Medicare and Medicaid: if the test is covered under Medicare Part B, Medicare Advantage, or Medicaid, the company lists $0 as the typical out-of-pocket cost. If Medicare does not cover it, you may be asked to sign an Advance Beneficiary Notice agreeing to pay.
- Commercial insurance: coverage varies by plan. The company says it will contact you first if your cost could exceed $330.
- Assistance: the company lists income-based financial assistance (generally not for Medicare or Medicaid patients) and an interest-free payment plan of up to 12 months for balances of $100 or more.
Many insurers require prior authorization and documentation of a diagnosis and a past medication failure or side effect. The lab bills you or your insurer directly, separate from your psychiatric visits.
You Need a Prescriber to Get a GeneSight Test
You cannot order GeneSight on your own. A clinician registered with the company must place the order, though patients can submit a request asking their clinician to register. If you have a consumer DNA kit report, share it with your prescriber before it affects a decision. Never start, stop, or change a medication on your own based on a genetic report. Before testing, ask how results could change your plan, what you will pay, and how treatment continues while you wait.
How Psychiatrists Use Results in Medication Management
In medication management, a psychiatrist reads the report alongside your history, not in place of it. Results may lead to a lower starting dose, slower increases, closer side effect monitoring, or a different drug in the same class. Our article on how SSRIs and SNRIs differ explains the basics.
The report also covers some ADHD medications, and our Vyvanse vs. Adderall comparison explains two common stimulants. Keep a copy of your results, because CYP2D6 and CYP2C19 also affect drugs outside psychiatry.
If you are in crisis or thinking about harming yourself, call or text 988 (Suicide and Crisis Lifeline). If there is immediate danger, call 911.
Frequently Asked Questions About GeneSight Testing
What Is GeneSight Testing?
GeneSight testing is a cheek-swab pharmacogenomic test, made by Myriad Genetics, that checks gene variants linked to how your body processes and responds to psychiatric medications. The report sorts more than 60 medications into green, yellow, and red categories. Your prescriber uses it as one input alongside your symptoms, history, and other medications. It does not diagnose a condition or pick a medication for you.
How Much Does GeneSight Testing Cost Without Insurance?
Without insurance, the company currently lists a reduced self-pay price of $330, and it says all patients are eligible for that option. Prices and program terms can change, so confirm your cost with the company before you test. The company also lists income-based financial assistance and an interest-free payment plan of up to 12 months for balances of $100 or more.
Is GeneSight Covered by Insurance or Medicare?
GeneSight is often covered, but coverage depends on your plan and on meeting its criteria. The company lists $0 as the typical out-of-pocket cost for Medicare Part B, Medicare Advantage, and Medicaid patients, though you may need to sign an Advance Beneficiary Notice if Medicare will not pay. Commercial plans vary, and many require prior authorization and a documented past medication failure or side effect.
Can I Order a GeneSight Test Myself?
No, you cannot order a GeneSight test yourself; a prescribing clinician who is registered with the company must place the order. That clinician can be a psychiatrist, primary care physician, or nurse practitioner. If your clinician is not registered, the company has a patient request form that can ask them to sign up, and it offers a directory of registered providers if you do not have one.
Does a Green GeneSight Result Mean a Medication Will Work for Me?
No, a green result does not mean a medication will work for you. It only means the tested genes do not predict an abnormal response, and the company itself notes that patients may not respond to green medications. Your diagnosis, dose, other medications, and time on a drug still shape the outcome, which is why your prescriber reads results alongside your full history.
How Long Does GeneSight Testing Take to Get Results?
Results typically reach your prescriber about three days after the lab receives your sample, though that timing is not guaranteed. If you use a mailed home kit, shipping time adds to the wait. Your prescriber then reviews the report with you. Treatment you need now should not be put on hold while you wait for results.
Is GeneSight Testing Accurate?
The genetic results are designed to be reliable, since the company states its laboratory is CLIA certified and CAP accredited, standards that cover lab quality and accurate results. Lab accuracy is not the same as clinical usefulness, though. In two large randomized trials of adults with depression, using the results led to only modest improvements, and most people in the testing groups still did not reach remission.
What Medications Does GeneSight Test For?
GeneSight covers more than 60 mental health medications used for depression, anxiety, ADHD, and other conditions. These include antidepressants, antipsychotics, anxiety and sleep medications, mood stabilizers, and ADHD stimulants and non-stimulants. The company updates its report over time, so ask your prescriber to check if a specific medication you are considering is included on your results.
Talk With a Psychiatrist About Your Medication Options
A genetic test can add information, but it works best inside a plan built from your history, symptoms, and goals. If you live in New York, New Jersey, or Pennsylvania and want help with depression treatment or a medication plan that has stalled, you can book a free 15-minute telehealth consultation to discuss your medication history and your options. A board-certified psychiatrist can review what you have tried and explain if pharmacogenomic testing makes sense for you.
